Kaitlyn D’Onofrio

DocwireNews

The randomized, double-blind BE ACTIVE trial compared bimekizumab versus placebo in patients with <a href="https://www.docwirenews.com/blog/when-to-see-a-rheumatologist-for-joint-pain/">active psoriatic arthritis</a>. According to the findings, bimekizumab was associated with significantly improved outcomes and an acceptable safety profile.&ldquo;Dual neutralisation of interleukin 17A (IL17A) and interleukin 17F (IL17F) is a potential novel therapeutic approach in psoriatic arthritis. We assessed bimekizumab, a monoclonal antibody that selectively neutralises IL17A and IL17F, in patients with active psoriatic arthritis,&rdquo; the study authors wrote.The phase 2B study spanned 41 sites across six countries (Czech Republic, Germany, Hungary, Poland, Russia, and the U.S.). Patients aged 18 years or older with active adult-onset psoriatic <a href="https://www.docwirenews.com/blog/blog-lifestyle-tips-for-those-suffering-from-rheumatoid-arthritis/">arthritis</a> with at least six months of symptoms were randomized to placebo, 16 mg bimekizumab, 160 mg bimekizumab, 160 mg bimekizumab with a one-off 320 mg loading dose, or 320 mg bimekizumab. Interventions were performed every four weeks for 12 weeks, at which time placebo and low-dose bimekizumab patients were randomized again to either 160 mg or 320 mg bimekizumab (the rest of the cohort continued its original course of treatment) for up to 48 weeks. Eligibility screening took place between Oct. 27, 2016, and July 16, 2018. Patients and researchers were both blinded to the intervention and dose during the initial 12 weeks as well as the subsequent period after re-randomization. The main outcome measure was the proportion of patients with at least 50% improvement in the American College of Rheumatology response criteria (ACR50) at week 12.Bimekizumab Outperforms Placebo at all DosesFinal analysis included 206 randomized <a href="https://www.docwirenews.com/docwire-pick/rheumatology-picks/kim-kardashians-lupus-scare-is-this-common/">patients</a>; 42 patients were assigned to placebo, and each active treatment group had 41 patients. Compared to the placebo group, the intervention groups had significantly better ACR50 response outcomes at week 12: 16 mg (odds ratio [OR]=4.2; 95% confidence interval [CI], 1.1&ndash;15.2; P=0.032), 160 mg (OR=8.1; 95% CI, 2.3&ndash;28.7; P=0.0012), and 160 mg (loading dose) (OR=9.7; 95% CI, 2.7&ndash;34.4; P=0.0004). Treatment-emergent adverse events (AEs) at the 12-week mark presented in 57% of placebo patients (n= 24) and 41% of patients in all of the bimekizumab groups (n = 68); most of the AEs were mild or moderate. Eight of the nine patients who sustained serious treatment-emergent AEs were in one of the bimekizumab groups. There were no recorded cases of death or inflammatory bowel disease.The study was published in <a href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)33161-7/fulltext">The Lancet</a>.&ldquo;Bimekizumab doses of 16 mg and 160 mg (with or without a 320 mg loading dose) were associated with significant improvements in ACR50 compared with placebo, with an acceptable safety profile. Our results support phase 3 investigation of bimekizumab as a treatment for psoriatic arthritis,&rdquo; concluded the researchers.

Jordana Jampel

Positive Preliminary Results From Phase 1 Trial of Dopaminergic Neuron Graft for Parkinson’s Disease

Dementia

Bradley Warady, MD

Joel M. Topf, MD, FACP

2025 Hume Award Winner Is Dedicated to Children’s Care

NKF Spring Clinical Meetings 2025

Distant Brain Metastases in Cutaneous Melanoma May Be Mitigated With Multiple Pathway Inhibitors

Melanoma

Latest News

Bimekizumab Is a Safe and Effective Treatment for Active Psoriatic Arthritis

Psoriatic Arthritis

The randomized, double-blind BE ACTIVE trial compared bimekizumab versus placebo in patients with active psoriatic arthritis. According to the findings, bimekizumab was ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe